Suppr超能文献

透析液钙浓度低于 3.0 mEq/L 与日本透析结局和实践模式研究中改善的结局无关。

Dialysate Calcium Concentration below 3.0 mEq/L Is Not Associated with Improved Outcomes in the Japanese Dialysis Outcomes and Practice Patterns Study.

机构信息

Clinical Research Support Center, Tomishiro Central Hospital, Okinawa,

Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.

出版信息

Nephron. 2018;140(4):240-248. doi: 10.1159/000493470. Epub 2018 Oct 19.

Abstract

BACKGROUND

Abnormal chronic kidney disease-mineral and bone disorder (CKD-MBD) markers have been associated with adverse outcomes in hemodialysis (HD) patients. Dialysate calcium concentration (D-Ca) likely influences serum calcium and phosphorus levels. Optimal D-Ca level remains unclear. We hypothesized that higher D-Ca is associated with cardiovascular events and mortality among Japanese HD patients.

METHODS

Enrollment data of chronic HD patients in the prospective observational study JDOPPS, phases 1-5 (1999-2015), provided exposures and covariates. All-cause mortality, non-arrhythmic cardiovascular events (NonAR-CVE), or their composites were analyzed by D-Ca, and divided into 2.5, 2.75, and 3.0 mEq/L. To minimize confounding by indication, analyses were restricted to facilities in which at least 90% of patients received the same D-Ca prescription. Association of D-Ca level with outcomes was evaluated in Cox models stratified by phase and accounting for facility clustering. Covariates describing patient demographics, comorbidities, laboratory values, CKD-MBD therapy, and facility attributes provided adjustment.

RESULTS

Of 9,201 patients included, 25.0% had D-Ca of 2.5 mEq/L; 6.8% D-Ca 2.75; and 68.2% D-Ca 3.0. Median follow-up time was 2.03 years. D-Ca was not associated with all-cause mortality, with hazards ratios for 2.5 vs. 3.0 mEq/L of 0.90 and 95% CI (0.73-1.11), nor with other outcomes. One effect modification occurred, protective for lower D-Ca on NonAR-CVE in the absence of cardiovascular comorbidities (p = 0.032), although corresponding D-Ca effects were not significant after multiple comparisons adjustment (p = 0.261 [D-Ca 2.5] and 0.125 [D-Ca 2.75]).

CONCLUSION

Lowering D-Ca level below 3.0 mEq/L seems not to have a meaningful effect on patient outcomes.

摘要

背景

异常的慢性肾脏病-矿物质和骨异常(CKD-MBD)标志物与血液透析(HD)患者的不良结局相关。透析液钙浓度(D-Ca)可能影响血清钙和磷水平。最佳 D-Ca 水平仍不清楚。我们假设较高的 D-Ca 与日本 HD 患者的心血管事件和死亡率相关。

方法

前瞻性观察研究 JDOPPS 的阶段 1-5(1999-2015 年)的慢性 HD 患者的入组数据提供了暴露和协变量。全因死亡率、非心律失常性心血管事件(NonAR-CVE)或其组合通过 D-Ca 进行分析,并分为 2.5、2.75 和 3.0 mEq/L。为了最大限度地减少指示性混杂,分析仅限于至少 90%的患者接受相同 D-Ca 处方的设施。在按阶段分层并考虑设施聚类的 Cox 模型中评估 D-Ca 水平与结局的关联,并对患者人口统计学、合并症、实验室值、CKD-MBD 治疗和设施特征进行了调整。

结果

在纳入的 9201 名患者中,25.0%的患者 D-Ca 为 2.5 mEq/L;6.8%为 D-Ca 2.75;68.2%为 D-Ca 3.0。中位随访时间为 2.03 年。D-Ca 与全因死亡率无关,2.5 与 3.0 mEq/L 的危险比为 0.90 和 95%CI(0.73-1.11),与其他结局也无关。发生了一种效应修饰,在没有心血管合并症的情况下,较低的 D-Ca 对 NonAR-CVE 具有保护作用(p=0.032),尽管在多次比较调整后,相应的 D-Ca 效应并不显著(p=0.261[D-Ca 2.5]和 0.125[D-Ca 2.75])。

结论

将 D-Ca 水平降低到 3.0 mEq/L 以下似乎对患者的结局没有明显的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验